Evidence map›Paper›PMID 28248311›Full record

ArticleNature communications2017

Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis.

Anh T Tran, Emma E Watson, Venugopal Pujari, Trent Conroy, Luke J Dowman, Andrew M Giltrap, Angel Pang, Weng Ruh Wong, Roger G Linington, Sebabrata Mahapatra and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. An allosteric inhibitor ofEMBO molecular medicine · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 4 countries.

Anh T TranSchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
Emma E WatsonSchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
Venugopal PujariMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, USA.
Trent ConroySchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
Luke J DowmanSchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
Andrew M GiltrapSchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
Angel PangCentenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia.
Weng Ruh WongDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, California 95064, USA.
Roger G LiningtonDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, California 95064, USA.ORCID 0000-0003-1818-4971
Sebabrata MahapatraMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, USA.
Jessica SaundersCentre for Drug Candidate Optimisation, Monash University, Melbourne, Victoria 3052, Australia.
Susan A CharmanCentre for Drug Candidate Optimisation, Monash University, Melbourne, Victoria 3052, Australia.
Nicholas P WestSchool of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Queensland 4067, Australia.
Timothy D H BuggDepartment of Chemistry, University of Warwick, Coventry CV4 7AL, UK.
Julie TodSchool of Life Sciences, University of Warwick, Coventry CV4 7AL, UK.
Christopher G DowsonSchool of Life Sciences, University of Warwick, Coventry CV4 7AL, UK.
David I RoperSchool of Life Sciences, University of Warwick, Coventry CV4 7AL, UK.ORCID 0000-0003-0009-621X
Dean C CrickMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, USA.
Warwick J BrittonCentenary Institute and Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia.
Richard J PayneSchool of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
The University of Sydney · AUUniversity of Warwick · GBColorado State University · USMonash University · AUQueensland University of Technology · AUSimon Fraser University · CAUniversity of California, Santa Cruz · US

Funding

Sterol/Hopanoid Biosynthesis: An Anti-TB Drug TargetR01AI049151 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI CRICK, DEAN C · 2001 to 2019
$4.1M
HTS assays for the methylerythritol-4-phosphate pathwayR01AI097550 · NIAID · COLORADO STATE UNIVERSITY · PI CRICK, DEAN C · 2012 to 2014
$1.1M
Menaquinone biosynthesis: a drug target in Gram-positive bacteriaR56AI049151 · NIAID · COLORADO STATE UNIVERSITY · PI CRICK, DEAN C · 2007 to 2007
$320k
Medical Research Council G0400848Medical Research Council G0500643Medical Research Council G1100127Medical Research Council MR/N002679/1NIAID NIH HHS R01 AI049151NIAID NIH HHS R01 AI097550NIAID NIH HHS R56 AI049151
6 · The paper itself

Abstract

Tuberculosis (TB) is responsible for enormous global morbidity and mortality, and current treatment regimens rely on the use of drugs that have been in use for more than 40 years. Owing to widespread resistance to these therapies, new drugs are desperately needed to control the TB disease burden. Herein, we describe the rapid synthesis of analogues of the sansanmycin uridylpeptide natural products that represent promising new TB drug leads. The compounds exhibit potent and selective inhibition of Mycobacterium tuberculosis, the etiological agent of TB, both in vitro and intracellularly. The natural product analogues are nanomolar inhibitors of Mtb phospho-MurNAc-pentapeptide translocase, the enzyme responsible for the synthesis of lipid I in mycobacteria. This work lays the foundation for the development of uridylpeptide natural product analogues as new TB drug candidates that operate through the inhibition of peptidoglycan biosynthesis.

Indexed as

AnimalsAntitubercular AgentsBiological ProductsHumansMiceMonosaccharidesMycobacterium tuberculosisOligopeptidesUridineAntitubercular AgentsBiological Productslipid IMonosaccharidesOligopeptidessansanmycinUridine

Identifiers

PMID28248311
PMCPMC5337940
OpenAlexW2594473237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.